However, due to the multifacial functions of HDAC inhibitors, a caveat that other mechanisms might also contribute to the anti-leukemia effect of chidamide alone and even in combination with MI-3 in MLL-r AML cells could not be excluded. This evidence concerns the gene KMT2A and acute myeloid leukemia.